Computer assisted decision support in acutely ill patients. Application in glucose management and quantification of myocardial reperfusion

Vogelzang, Mathijs

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date: 2008

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 09-01-2019
Chapter 8

Computer-assisted glucose control in critically ill patients

Mathijs Vogelzang, Bert G. Loef, Joost G. Regtien, Iwan C. C. van der Horst, Hein van Assen, Felix Zijlstra, Maarten W. N. Nijsten

Intensive Care Med 2008, accepted
Abstract

Objective Intensive insulin therapy is associated with the risk of hypoglycemia and increased costs of material and personnel. We therefore evaluated the safety and efficiency of a computer-assisted glucose control protocol in a large population of critically ill patients.

Design Observational cohort study.

Setting Three intensive care units (32 beds) in a 1300-bed university teaching hospital.

Patients All 2800 patients admitted to the surgical, neurosurgical, and cardiothoracic units; the study period started at each ICU after implementation of Glucose Regulation for Intensive care Patients (GRIP), a freely available computer-assisted glucose control protocol.

Measurements and results We analyzed compliance to recommended insulin pump rates and glucose measurement frequency. Patients were on GRIP-ordered pump rates 97% of time. Median measurement time was 5 minutes late (IQR 20m early to 34m late). Hypoglycemia was uncommon (7% of patients for mild hypoglycemia, <3.5 mmol/L; 0.86% for severe hypoglycemia, <2.2 mmol/L). Our predefined target range (4.0-7.5 mmol/L) was reached after a median (IQR) time of 5.6 (0.2 - 11.8) hours, and maintained for 89% (70-100%) of the remaining length of stay at the ICU. The number of measurements needed was 5.9 (4.8 - 7.3) per patient per day. In-hospital mortality was 10.1%.

Conclusions Our computer-assisted glucose control protocol provides safe and efficient glucose regulation in routine intensive care practice. A low rate of hypoglycemic episodes was achieved with a considerably lower number of glucose measurements than used in most other schemes.

Introduction

Glucose control with intensive insulin therapy in critically ill medical and surgical patients reduces morbidity and mortality.\textsuperscript{1,2} However, this therapy carries the risk of hypoglycemia. Although little is known about the impact of hypoglycemia, cases with severe sequelae have been reported.\textsuperscript{3–5} Recently, a retrospective review has found that the occurrence of a single episode of hypoglycemia is related to mortality.\textsuperscript{6} Due to the high rate of insulin-induced hypoglycemia, a multicenter trial has been
stopped, and negative results have led to debate about the overall benefit of glucose control.\textsuperscript{7,8} Therefore, a meticulous scheme of glucose measurements and subsequent insulin-dosing adjustments must be implemented. Such a scheme should accomplish adequate control with as few glucose measurements as possible with minimal risk of hypoglycemia. Many insulin infusion protocols have been proposed, but performance is difficult to compare,\textsuperscript{9} and the size of reported patient cohorts is often small. As hypoglycemia is and should be a rare event, no firm conclusions can be drawn from small populations. Furthermore, a research setting in which a protocol is tested on selected patients may not reflect the performance of a protocol when used in routine practice. We implemented a computer-assisted glucose control system in routine practice and evaluated its safety and efficiency in a large cohort of unselected consecutive patients in three ICUs.

Materials and Methods

GRIP computer program

The Glucose Regulation for Intensive care Patients (GRIP) computer program gives recommendations on exact insulin pump rates and glucose measurement frequency for all patients. It also acts as watchdog against overdue measurements. Initial results and a description of the GRIP computer program have previously been reported.\textsuperscript{10} In short, the GRIP program is installed on a computer directly next to the point of care blood gas analyzer. By default the computer shows an overview of the ICU. The colors of the beds make clear whether a specific action (such as taking a new blood glucose or modifying an insulin pump) should be performed at a certain bed. New glucose values are automatically queried from the hospital information system. These values are combined with clinical data obtained from the nurse, and recommendations on both the insulin pump rate and the measurement interval can be calculated at any moment. The algorithm employed by GRIP is based on both the level and the change in recent glucose values. A more detailed description of the algorithm is given in the accompanying Electronic Supplementary Material. GRIP was designed with practical applicability in mind; where possible, we aimed at limiting the number of blood glucose measurements needed and thus the time spent on glucose control. The total turn-around time for a nurse, from glucose measurement to final pump change was measured to be 4 minutes.

In 2005 we implemented an improved version that incorporates more safety features, such as label printing, rendering the entire procedure paperless. The complete source code of the GRIP computer program is freely available from the website.
http://grip-glucose.sf.net/.

The insulin dosing of GRIP is flexible with regard to its target value. In view of the debated value of aiming for true normoglycemia (4.4-6.1 mmol/L), the medical directors (MN, BL and JR) preferred a more lenient glucose range of 4.0-7.5 mmol/L, and therefore GRIP was configured to aim for a glucose level of 6.5 mmol/L. It should be noted that changing the algorithm’s target value is trivial.

Implementation of GRIP

All ICUs that have implemented GRIP are part of the University Medical Center Groningen, a 1300-bed tertiary university hospital. All three ICUs are closed-format ICUs with a nursing to patient ratio of one-to-one. The three units are teaching general surgery, anesthesiology and internal medicine residents, and fellows in intensive care medicine. GRIP was first implemented at the surgical ICU, followed by the cardiothoracic and neurosurgical ICU. In dialog with staff the initial target level was 7.0 mmol/L for the cardiothoracic ICU and 7.5 mmol/L for the neurosurgical ICU. Nurses were trained by a “teach-the-teacher” principle, where two or three nurses of each ICU were trained at the surgical ICU, after which they taught the colleagues at their own unit. After a run-in period the GRIP target level was lowered to 6.5 mmol/L.

Patients

We included 2800 admissions with 73188 glucose measurements for analysis; Table 1 presents patients’ characteristics. We recorded baseline demographics, reason for admission, and severity of illness as measured by Acute Physiology and Chronic Health Evaluation (APACHE) II scores [median 15, interquartile range (IQR) 10-19]. We excluded the patients who were treated by GRIP in any of the run-in periods. Figure 1 shows a patient selection diagram.

The dark colored squares indicate a ‘run-in’ period. The patients treated by GRIP in these periods were not analyzed in this study.
Table 8.1: Patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>Surgical ICU</th>
<th>Thoracic ICU</th>
<th>Neurosurgical ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>1073 (38%)</td>
<td>1597 (57%)</td>
<td>130 (5%)</td>
</tr>
<tr>
<td>Treatment period</td>
<td>Feb. 2005-</td>
<td>Jan. 2006-</td>
<td>Mar. 2007-</td>
</tr>
<tr>
<td>Age</td>
<td>62 (50-72)</td>
<td>66 (57-74)</td>
<td>55 (46-65)</td>
</tr>
<tr>
<td>Male sex</td>
<td>663 (62%)</td>
<td>1096 (69%)</td>
<td>76 (62%)</td>
</tr>
<tr>
<td>APACHE II</td>
<td>14 (10 - 19)</td>
<td>14 (10 - 18)</td>
<td>12 (7 - 17)</td>
</tr>
<tr>
<td>Reason of admission</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiothoracic surgery</td>
<td>13 (1.2%)</td>
<td>1303 (82%)</td>
<td>1 (0.8%)</td>
</tr>
<tr>
<td>Abdominal surgery</td>
<td>512 (48%)</td>
<td>17 (1.1%)</td>
<td>9 (6.9%)</td>
</tr>
<tr>
<td>Neurological</td>
<td>67 (6.3%)</td>
<td>24 (1.5%)</td>
<td>103 (79%)</td>
</tr>
<tr>
<td>Cardiac arrest</td>
<td>10 (0.9%)</td>
<td>137 (8.6%)</td>
<td>1 (0.8%)</td>
</tr>
<tr>
<td>Trauma</td>
<td>150 (14%)</td>
<td>12 (0.8%)</td>
<td>5 (3.8%)</td>
</tr>
<tr>
<td>Vascular surgery</td>
<td>106 (10%)</td>
<td>18 (1.1%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Medical</td>
<td>57 (5.3%)</td>
<td>30 (1.9%)</td>
<td>8 (6.2%)</td>
</tr>
<tr>
<td>Post-transplant</td>
<td>45 (4.2%)</td>
<td>10 (0.6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>113 (11%)</td>
<td>46 (2.9%)</td>
<td>3 (2.3%)</td>
</tr>
<tr>
<td>In-hospital mortality</td>
<td>147 (14%)</td>
<td>117 (7.3%)</td>
<td>19 (15%)</td>
</tr>
<tr>
<td>Total number of patient-days</td>
<td>8359</td>
<td>5137</td>
<td>752</td>
</tr>
<tr>
<td>Admission glucose</td>
<td>7.8 (6.5 - 9.5)</td>
<td>8.6 (7.3 - 10)</td>
<td>7.5 (6.5 - 8.9)</td>
</tr>
<tr>
<td>Time to reach target range (hours)</td>
<td>4 (0 - 9)</td>
<td>9 (2 - 13)</td>
<td>2 (0 - 6)</td>
</tr>
<tr>
<td>Glucose after 24h</td>
<td>6.7 (6.0 - 7.4)</td>
<td>6.5 (5.9 - 7.2)</td>
<td>6.8 (6.1 - 7.7)</td>
</tr>
<tr>
<td>Glucose SD</td>
<td>1.1 (0.7-1.7)</td>
<td>1.3 (0.9-1.8)</td>
<td>1.0 (0.7-1.4)</td>
</tr>
</tbody>
</table>

All patients were managed by GRIP. Orders of GRIP could be overruled at the discretion of the physician at any time, or a patient could be taken out of GRIP altogether. The latter happened structurally with patients who had recovered enough to be taking meals. During intermittent invasive interventions insulin was stopped. The local institutional review board approved this study.

Glucose parameters

Glucose measurements were performed in arterial blood samples when an arterial line was present and in venous blood otherwise. All ICUs had a point-of-care blood gas analyzer on which glucose measurements were performed (ABL 700 or 800 series, Radiometer, Copenhagen, Denmark). For each glucose measurement the recommended measurement time was compared with the actual measurement time. We classified these times in lowest, middle two, and highest quartiles. For measurements in each group we determined whether the glucose level was in the desired range, and what
the change in insulin pump rate was after that measurement. Actual pump rates were compared to the recommended pump rate at each time point. We determined the linearly interpolated glucose value of each patient at 3-hour intervals after admission for the first 48 hours to visualize the general decrease in glucose achieved by GRIP directly after admission to the unit. Low glucose values were scored as mild hypoglycemia (<3.5 mmol/L) or severe hypoglycemia (<2.2 mmol/L) and expressed as the proportion of all patients, and as the number of episodes per 1000 patient-days.

To assess the ability of the program to reduce hyperglycemia we determined the time from admission until the first measurement that was in our target range (4.0-7.5 mmol/L). We also determined the amount of time spent within the target range, both for the full length of stay and for the period after first reaching the target range. We also calculated the hyperglycemic index (HGI), a measure of overall hyperglycemia. Recently glucose variability has been proposed as control target of glucose management. We therefore determined blood glucose variability by taking the standard deviation of all measurements of a patient.

Statistics

All statistics were calculated with R version 2.2.4 (http://www.r-project.org). Variables are presented as medians and IQR. Comparisons between groups were made with the Mann-Whitney U test, Fisher’s exact test, or the Chi square test. A P value <0.05 was considered statistically significant.

Results

Glucose control

Median time between patient admission and the first glucose entered into GRIP generating a recommendation was 21 (6-65) minutes. Compliance with GRIP-recommended pump rates was 97%. Compared with the recommended measurement time, the median measurement was 5 minutes late (IQR 20 minutes early to 34 minutes late).

Table 2 shows characteristics of glucose measurements and insulin pump interventions for early, on-time, and late measurements. Incidence of measurements <4.0 mmol/L was slightly lower with early than ontime measurements (P=0.04), but late measurements were more often low (P=0.03). Hypoglycemia was uncommon, with 0.86% of patients experiencing a glucose level lower than 2.2 mmol/L during any moment of their stay and 7% for a level of 3.5 mmol/L. Per 1000 patient-days of ICU stay there were 1.6 measurements lower than 2.2 mmol/L and 14.4 measurements lower than 3.5 mmol/L.
Table 8.2: Compliance with measurement time

<table>
<thead>
<tr>
<th></th>
<th>Early</th>
<th>On time</th>
<th>Late</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>18357 (25%)</td>
<td>36805 (50%)</td>
<td>18026 (25%)</td>
</tr>
<tr>
<td>Time</td>
<td>&gt;20m early</td>
<td>-20m to +34m</td>
<td>&gt;34m late</td>
</tr>
<tr>
<td>Glucose level (percentage of time group)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypo (&lt;2.2 mmol/L)</td>
<td>0.03%</td>
<td>0.03%</td>
<td>0.07%</td>
</tr>
<tr>
<td>Low (2.2 - 4 mmol/L)</td>
<td>0.8%</td>
<td>1.0%</td>
<td>1.3%</td>
</tr>
<tr>
<td>In range (4 - 7.5 mmol/L)</td>
<td>74%</td>
<td>66%</td>
<td>70%</td>
</tr>
<tr>
<td>High (&gt;7.5 mmol/L)</td>
<td>25%</td>
<td>33%</td>
<td>29%</td>
</tr>
<tr>
<td>Insulin change (percentage of time group)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decrease &gt;1 IU/h</td>
<td>6.3%</td>
<td>11.9%</td>
<td>10.1%</td>
</tr>
<tr>
<td>Decrease 0.5 - 1 IU/h</td>
<td>7.3%</td>
<td>9.9%</td>
<td>9.1%</td>
</tr>
<tr>
<td>Small change (-0.5 to +0.5 IU/h)</td>
<td>68%</td>
<td>52%</td>
<td>58%</td>
</tr>
<tr>
<td>Increase 0.5 - 1 IU/h</td>
<td>10.2%</td>
<td>12.5%</td>
<td>10.7%</td>
</tr>
<tr>
<td>Increase &gt;1 IU/h</td>
<td>8.1%</td>
<td>13.9%</td>
<td>11.7%</td>
</tr>
</tbody>
</table>

The table shows data for the lowest ("early") middle two ("on time") and highest quartile ("late") of measurement times. For each category, the number of measurements in range is shown and how much the pump rate was adjusted after that measurement. Overall distribution of glucose levels and insulin changes was different for each group (χ² test, P<0.001).

Figure 2 graphically shows glucose control directly after admission to the ICU. Admission glucose decreased from 8.3 (6.9-9.8) mmol/L to 6.6 (6.0-7.4) mmol/L at 24 hours (P<0.001). Time from admission to a value within the desired range was 5.6 (0.2-11.8) hours. After that time patients stayed within range for 89 (70-100)% of their remaining stay. Due to the inclusion of a significant number of short stay patients, for which the time to establish initial control represents a relatively large part of their total stay, the overall time in range was 67%. The hyperglycemic index (HGI) was 1.24 (0.8-1.76) mmol/L. The patients in the lowest quartile of time in range had higher APACHE II scores, higher insulin doses, less compliance with the recommended insulin rate, more frequent measurements, and a higher incidence hypoglycemia. Median number of glucose measurements per day of stay was 5.9 (4.7-7.3), i.e., once every 245 minutes. The glucose variability was 1.22 (0.8-1.75) mmol/L.

Discussion

This study evaluated computer-assisted glucose control in routine practice over a 3-year period at three ICUs with different patient populations. With a reasonable glucose target level, we found that glucose control was adequate and safe, with low rates of hypoglycemia. Importantly, the protocol was feasible with six measurements per
Safety is a major concern in contemporary health care. While the efficacy of glucose control is debated, implementation should be particularly safe. Reducing the possibility of human cognitive failing is a generic way to improve safety in healthcare. Prior to our study it was shown that standardization by paper protocol improves glucose control, and that computer-assisted protocols are feasible and lead to better compliance than protocols on paper. Recommendations of pump rates and measurement intervals and the notification of expiration of the interval, combined with the possibility of overruling, provide a flexible standardization of glucose control in the ICU.

Comparison with protocols from the literature is difficult because of wide variations in target glucose levels, patient populations, and metrics of control reported. We performed a literature search to find all computerized glucose protocols designed for ICU patients and tested in at least 20 patients. We summarize these findings in table 3. Similar to what is reported for paper protocols, reported target ranges, patient populations, and measurement means vary greatly. However, we can conclude that
### Computer-assisted glucose control in critically ill patients

#### Table 8.3: Comparison with other computer-assisted glucose control protocols and intervention groups from clinical trials.

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Patient type</th>
<th>APACHE range</th>
<th>Hypoglycemia &amp; Performance Measurements</th>
<th>Hyperglycemia</th>
<th>Severe episodes</th>
<th>Mean 6.2 mmol/L</th>
<th>% of patients &gt; 7.8 mmol/L</th>
<th>Mean 5.7 mmol/L</th>
<th>% of patients &gt; 2.2 mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hovorka</td>
<td>16</td>
<td>Cardiac surgery</td>
<td>4.4-6.1</td>
<td>57% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>20</td>
<td>4.4-6.1</td>
<td>19% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>5% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Shulman</td>
<td>50</td>
<td>Mixed ICU</td>
<td>4.4-6.1</td>
<td>73% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>23</td>
<td>4.4-6.1</td>
<td>15% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>9% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Hermayer</td>
<td>66</td>
<td>CABG</td>
<td>4.4-6.7</td>
<td>54% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>15</td>
<td>4.4-6.1</td>
<td>13% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>6% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Rood</td>
<td>19</td>
<td>Mixed ICU</td>
<td>4.0-7.0</td>
<td>85% of patients &gt; 7.8 mmol/L</td>
<td>4.0-7.0</td>
<td>20</td>
<td>4.0-7.0</td>
<td>4% of patients &gt; 7.8 mmol/L</td>
<td>4.0-7.0</td>
<td>1% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Toschlog</td>
<td>128</td>
<td>Trauma</td>
<td>4.4-6.1</td>
<td>73% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>15</td>
<td>4.4-6.1</td>
<td>3% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>0% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Meynaar</td>
<td>280</td>
<td>Mixed ICU</td>
<td>4.5-7.5</td>
<td>59% of patients &gt; 7.8 mmol/L</td>
<td>4.5-7.5</td>
<td>20</td>
<td>4.5-7.5</td>
<td>12% of patients &gt; 7.8 mmol/L</td>
<td>4.5-7.5</td>
<td>5% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Boord</td>
<td>204</td>
<td>Surgical ICU</td>
<td>4.4-6.1</td>
<td>83% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>15</td>
<td>4.4-6.1</td>
<td>3% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>0% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Thomas</td>
<td>22</td>
<td>Single ICU</td>
<td>4.4-6.1</td>
<td>63% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>15</td>
<td>4.4-6.1</td>
<td>1% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>0% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Davidson</td>
<td>34</td>
<td>General medical and surgical floors</td>
<td>4.0-7.0</td>
<td>50% of patients &gt; 7.8 mmol/L</td>
<td>4.0-7.0</td>
<td>14</td>
<td>4.0-7.0</td>
<td>0% of patients &gt; 7.8 mmol/L</td>
<td>4.0-7.0</td>
<td>0% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Thomas</td>
<td>764</td>
<td>Medical</td>
<td>4.4-6.1</td>
<td>54% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>23</td>
<td>4.4-6.1</td>
<td>13% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>4% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>van den Berghe</td>
<td>595</td>
<td>Medical</td>
<td>4.4-6.1</td>
<td>43% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>15</td>
<td>4.4-6.1</td>
<td>11% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>3% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Brunkhorst</td>
<td>247</td>
<td>Severe sepsis</td>
<td>20 4.4-6.1</td>
<td>34% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>17</td>
<td>4.4-6.1</td>
<td>10% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>2% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>van den Berghe</td>
<td>1</td>
<td>Surgical</td>
<td>4.4-6.1</td>
<td>43% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>15</td>
<td>4.4-6.1</td>
<td>11% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>3% of patients &gt; 2.2 mmol/L</td>
</tr>
</tbody>
</table>

*Hypoglycemia is represented as the proportion of all measurements (as opposed to proportion of patients), unless otherwise specified.

- Hypoglycemia is represented as the proportion of all measurements (as opposed to proportion of patients), unless otherwise specified.
- No data, but methods state "hourly to two-hourly measurements".
- Calculated from number of measurements and length of stay.
- No data, but protocol has hourly to two-hourly measurements.
- No data, but methods state "hourly to four-hourly measurements".

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Patient type</th>
<th>APACHE range</th>
<th>Hypoglycemia &amp; Performance Measurements</th>
<th>Hyperglycemia</th>
<th>Severe episodes</th>
<th>Mean 6.2 mmol/L</th>
<th>% of patients &gt; 7.8 mmol/L</th>
<th>Mean 5.7 mmol/L</th>
<th>% of patients &gt; 2.2 mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>This study</td>
<td>88</td>
<td>Mixed ICU</td>
<td>4.0-7.0</td>
<td>50% of patients &gt; 7.8 mmol/L</td>
<td>4.0-7.0</td>
<td>20</td>
<td>4.0-7.0</td>
<td>15% of patients &gt; 7.8 mmol/L</td>
<td>4.0-7.0</td>
<td>5% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Juneja</td>
<td>204</td>
<td>Single ICU</td>
<td>4.4-6.1</td>
<td>83% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>15</td>
<td>4.4-6.1</td>
<td>3% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>0% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Thomas</td>
<td>22</td>
<td>Single ICU</td>
<td>4.4-6.1</td>
<td>63% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>15</td>
<td>4.4-6.1</td>
<td>1% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>0% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Boord</td>
<td>204</td>
<td>Surgical ICU</td>
<td>4.4-6.1</td>
<td>83% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>15</td>
<td>4.4-6.1</td>
<td>3% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>0% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Thomas</td>
<td>764</td>
<td>Medical</td>
<td>4.4-6.1</td>
<td>54% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>23</td>
<td>4.4-6.1</td>
<td>13% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>4% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>Brunkhorst</td>
<td>247</td>
<td>Severe sepsis</td>
<td>20 4.4-6.1</td>
<td>34% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>17</td>
<td>4.4-6.1</td>
<td>10% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>2% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>van den Berghe</td>
<td>1</td>
<td>Surgical</td>
<td>4.4-6.1</td>
<td>43% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>15</td>
<td>4.4-6.1</td>
<td>11% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>3% of patients &gt; 2.2 mmol/L</td>
</tr>
<tr>
<td>van den Berghe</td>
<td>1</td>
<td>Medical</td>
<td>4.4-6.1</td>
<td>43% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>15</td>
<td>4.4-6.1</td>
<td>11% of patients &gt; 7.8 mmol/L</td>
<td>4.4-6.1</td>
<td>3% of patients &gt; 2.2 mmol/L</td>
</tr>
</tbody>
</table>

Table 8.3: Comparison with other computer-assisted glucose control protocols and intervention groups from clinical trials.
compared with the studies published thus far, the present study is one of the largest to date and compares favorably in terms of occurrence of hypoglycemia and achievement of the target range. Interestingly, only one other published computer protocol\textsuperscript{20} seems to be aiming at achieving control with a low measurement frequency. This is remarkable, as glucose control with a high measurement frequency is associated with significant costs in terms of nursing effort and supplies.\textsuperscript{26} The glucose variability, which has recently been proposed as an important determinant of control,\textsuperscript{12} was 1.22 mmol/L in our large cohort. This is lower than the figures published previously, which were $1.7 \pm 1.3$ in survivors and $2.3 \pm 1.6$ in nonsurvivors.\textsuperscript{12}

The protocol GRIP used is published as open source, and the program can therefore be used freely by any hospital able to implement the bridge between GRIP and the hospital information system. We recognize that few hospitals have such resources, and we therefore provided a more detailed description of the algorithm in an online supplement, including typical recommendations for two example patients. Computer-based protocols published to date broadly fall into three categories: flow-chart based, empirical formula based, and model-based. Most paper protocols that are directly computerized fall into the first category. GRIP uses a formula empirically derived from many protocols and expert knowledge. Model-based approaches model glucose dynamics in different compartments and try to predict future glucose levels and insulin need from that. There have been no direct comparisons of different computer algorithms to date, and more research is needed to identify the best approach.

Our study has a number of strengths. We studied a large number of patients treated in routine practice. This provides a less biased view on true performance and rate of hypoglycemia than studies of glucose protocols in a research setting. The low number of measurements required by GRIP makes the protocol less time consuming than protocols with hourly measurements. The low average number of measurements GRIP requires is mainly caused by the flexibility of the interval algorithm. GRIP performs frequent measurements when needed, but this is counterbalanced by identification of stable periods during a patient’s stay (e.g., with steady glucose levels, full caloric intake and low insulin dose) during which much longer intervals can safely be recommended. Another strength is our analysis of actual compliance to the protocol. Prior publications of protocols rarely mention compliance metrics. Good performance attributed to a protocol that is violated often by nurses (by for instance measuring glucose earlier than recommended) can lead to disappointing results when strictly followed at another unit. In our analysis we find no structural violation of the protocol in terms of early and late measurements, and only late measurements were associated with more glucose values that were out of range.

Our study also has a number of limitations. Our choice of target glucose level (6.5...
mmol/L) may be regarded as either low or high, as the optimal target glucose level is currently an open question. True adherence to normoglycemia would require a lower target range than we used. The number of measurements asked for by GRIP depends on the expected risk of hypoglycemia, which becomes higher when aiming for a lower target. We therefore expect that a lower target level would increase GRIP’s recommended measurement frequency without a significant increase in hypoglycemic episodes, but we have not yet tested this. Clinical decision support tools may be less likely to be successful in a setting in which they were not developed. As the ICUs in our center function independently, and the development process has been limited solely to the surgical ICU, we expect that limitations of generalizability would have been uncovered in the implementation process, or would have been shown by inferior performance on the two other ICUs.

A computer program also brings benefits that we did not study, such as straightforward auditing of performance and easy incorporation of future changes in practice. For instance, when newly published evidence would favor a different target range, a quick adoption of the new preferred practice is possible without going through a learning period for nurses and physicians. In conclusion, our study shows that a computer-assisted protocol can safely and efficiently guide glucose control at intensive care units in routine practice.

References


24. Davidson PC, Steed RD, Bode BW. Glucommander: a computer-directed intravenous
insulin system shown to be safe, simple, and effective in 120,618 h of operation. *Diabetes Care* 2005;28(10):2418–2423.


